Related Experiment Video
Updated: Jul 6, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
To what extent should we lower HbA1c in diabetic subjects?
S Hadjadj1, P-J Saulnier, F Torremocha
1CHU de Poitiers, Department of Endocrinology Diabetology, 2, rue de la Milètrie, BP 577, 86021 Poitiers cedex, France. s.hadjadj@chu-poitiers.fr
Diabetes & Metabolism
|April 12, 2008
Summary
Current guidelines recommend HbA1c levels below 6.5% for diabetes management, particularly for preventing retinopathy. The benefit for cardiovascular disease risk reduction requires further investigation in ongoing studies.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Disease Research
- Diabetology
Background:
- Current diabetes management guidelines advocate for Hemoglobin A1c (HbA1c) levels below 6.5%.
- Evidence supports this target for reducing microvascular complications, specifically retinopathy.
- The efficacy of stringent glycemic control for cardiovascular disease (CVD) prevention remains an area of active research.
Purpose of the Study:
- To evaluate the current evidence supporting HbA1c targets for diabetes management.
- To clarify the relationship between HbA1c levels and microvascular versus macrovascular complications.
- To identify the need for further research into optimal glycemic control strategies for cardiovascular health.
Main Methods:
- Review of existing clinical trial data and epidemiological studies on glycemic control and diabetes complications.
- Analysis of data focusing on microvascular outcomes (retinopathy, nephropathy) and cardiovascular events.
- Identification of ongoing clinical trials addressing the role of very low HbA1c levels in CVD prevention.
Main Results:
- Strong evidence links HbA1c levels below 6.5% to reduced risk of retinopathy.
- Data regarding the impact of strict glycemic control on nephropathy is less conclusive compared to retinopathy.
- The "lower the better" hypothesis for HbA1c in relation to cardiovascular disease requires further validation.
Conclusions:
- While HbA1c targets below 6.5% are effective for preventing retinopathy, their role in preventing cardiovascular disease needs further elucidation.
- Ongoing studies are crucial for definitively answering whether a strategy of very low HbA1c improves cardiovascular outcomes.
- Future research should focus on personalized glycemic control strategies considering individual risk factors for microvascular and cardiovascular complications.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...